|Chemical and physical data|
|Molar mass||295.34 g/mol g·mol−1|
|3D model (JSmol)|
GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor, which presumably would produce stimulant effects in vivo.[original research?] Its DRI activity is shared by numerous addictive drugs including amphetamine and its derivatives (e.g. dextromethamphetamine), cocaine, and methylphenidate and its derivatives (e.g. ethylphenidate). However, dopaminergic drugs are also prone to producing emetic effects such as in the case of apomorphine.
- GYKI-52,466, another 2,3-benzodiazepine with other than GABAergic function
- Substituted methylenedioxyphenethylamine
- Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F. Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor. European Journal of Pharmacology. 1990; 183(4):1416-1417.
- Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, Lai HL, Chern Y. Modulation of Dopamine Transporter Activity by Nicotinic Acetylcholine Receptors and Membrane Depolarization in Rat Pheochromocytoma PC12 Cells. Journal of Neurochemistry. 1999; 72(6): 2437–2444.
* atypical activity profile (not GABAA receptor ligands)
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|